SBM Sirona Biochem Corp.

Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Aging Serum Formulations

Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Aging Serum Formulations

VANCOUVER, British Columbia, March 13, 2024 (GLOBE NEWSWIRE) -- . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona” or the “Company”) announces a significant achievement in its quest to transform the skincare industry. Its subsidiary, TFChem, has successfully received formulations for its eagerly awaited GlycoProteMim™ based anti-aging serum from its formulation partner, Global Beauty Consulting (GBC). This marks a crucial step in Sirona Biochem's plan to offer innovative skincare solutions.

The chosen formulation will not only define the brand but also lay the foundation for a broader range of products. The team is in the process of selecting the precise formulation that will undergo standard safety evaluations and be used in the upcoming clinical trial. This is in preparation for the planned product launch in early 2025, ensuring compliance with regulatory standards in the European, US, and Canadian markets.

‘We are thrilled to unveil these innovative formulations for our GlycoProteMim based anti-aging serum. Our mission at Sirona Biochem is to revolutionize skincare through science and these formulations represent a significant step towards achieving that goal.” reports Sirona’s Chief Scientific Officer Dr Geraldine Deliencourt-Godfrey. In line with our commitment to transparency and innovation, samples of the GlycoProteMim-based anti-aging serum formulations will be distributed to prospective key stakeholders in Asia, Europe, and North America.

About Sirona Biochem Corp.

Sirona is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit .

For more information regarding this press release, please contact:

Investor Enquiries:

Christopher Hopton

Chief Financial Officer

Phone: (604) 641-4466

Email:

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements

This news release includes certain statements that may be deemed “forward-looking statements”. All statements in this new release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.



EN
13/03/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sirona Biochem Corp.

 PRESS RELEASE

Sirona Biochem Engages Stonegate Healthcare Partners

Sirona Biochem Engages Stonegate Healthcare Partners VANCOUVER, British Columbia, May 07, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) has announced a partnership with Stonegate Healthcare Partners. Stonegate is a leading corporate advisory firm based in Dallas, Texas that offers research driven business development and investor outreach services. Leveraging Stonegate’s extensive global network of corporate and institutional investor relationships, Stonegate has begun an evaluation of Sirona’s anti-aging ingredient, GlycoProteMimTM, to effectively ass...

 PRESS RELEASE

SIRONA BIOCHEM Corporate Update April 2024

SIRONA BIOCHEM Corporate Update April 2024 VANCOUVER, British Columbia, April 08, 2024 (GLOBE NEWSWIRE) -- . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona” or the “Company”) provides the following update: Dear shareholders, We are pleased to provide an update on our recent milestones and strategic decisions shaping Sirona Biochem’s path forward. AGM Last week, during our Annual General Meeting (AGM), we successfully gained another year of backing for our management team. Although it's common for many shareholders to abstain from voting, we're pleased to report that we'...

 PRESS RELEASE

Sirona Biochem Announces Close of Private Placement

Sirona Biochem Announces Close of Private Placement VANCOUVER, British Columbia, April 04, 2024 (GLOBE NEWSWIRE) -- Vancouver, British Columbia – April 4, 2024 – . (TSX-V: SBM) (Frankfurt: ZSB) (“Sirona”) has closed its private placement (Private Placement”) for gross proceeds of $132,500 CAD. The Private Placement consists of 1,325,000 units, (the “Units”) at a price of $0.10 per Unit. Each Unit consists of one common share and one transferable share purchase warrant, each whole warrant exercisable into one additional common share of the Company for a period of 2 years from the date of i...

 PRESS RELEASE

Sirona Biochem Announces 2023 Annual Meeting Results

Sirona Biochem Announces 2023 Annual Meeting Results VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) announces the voting results from its Annual General Meeting of Shareholders (the "Meeting"), held in Vancouver, British Columbia on March 28, 2024. The total number of shares represented by shareholders present in person and by proxy at the Meeting was 26,722,196, representing 10.52% of Sirona's issued and outstanding Common Shares. All matters put forward to shareholders for consideration and approval, as set out in the ...

 PRESS RELEASE

Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Agin...

Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Aging Serum Formulations VANCOUVER, British Columbia, March 13, 2024 (GLOBE NEWSWIRE) -- . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona” or the “Company”) announces a significant achievement in its quest to transform the skincare industry. Its subsidiary, TFChem, has successfully received formulations for its eagerly awaited GlycoProteMim™ based anti-aging serum from its formulation partner, Global Beauty Consulting (GBC). This marks a crucial step in Sirona Biochem's plan to offer innovative skincare solutions. The chose...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch